Poly Medicure Q3 FY26 results: PAT Rs 78 cr, ESOP grant of 2,000 options

Exceptional ItemResults View source PDF Explain this filing

POLYMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹1515.00

prior close

₹1503.10

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.0%+0.2% vs market

Medical Equipment & Supplies peers, median of 10sector-0.1%-0.8% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty Smallcap 250 and 0.8 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

+0.2

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9-1.0+0.2-0.1-0.8

Next day

-8.5-1.4-7.1-0.3-8.2

-3.6+1.1-4.7+1.3-4.9

-1.9+1.6-3.6+1.9-3.8

-8.3+1.8-10.1+0.0-8.3

-13.2+1.0-14.2+0.8-14.0

-14.2-0.6-13.5-2.8-11.3

15d

-16.9-0.2-16.6-3.9-13.0

-9.6-3.8-5.7-3.4-6.2

-9.7-7.5-2.2-10.3+0.6

+6.7+5.2+1.4-3.4+10.0

UpDownMarket · Nifty Smallcap 250Sector · Medical Equipment & Supplies peers, median of 10Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Poly Medicure reported Q3 and 9M FY26 results. Standalone Q3 PAT Rs 78.4 cr (EPS Rs 7.73), 9M PAT Rs 255.4 cr (EPS Rs 25.20). Consolidated 9M PAT attributable to owners Rs 337.2 cr (EPS Rs 33.40). Results include Rs 6.80 cr one-time Labour Codes charge as exceptional item. Auditor gave clean review. Board granted 2,000 stock options at Rs 100 under ESOP 2020. Two acquisitions consolidated - Pendracare group and Citieffe group.

Likely market impact

Steady results with minor PAT growth. Two overseas acquisitions (Pendracare, Citieffe) to broaden medical device portfolio. Negligible ESOP dilution.